Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10151)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Oct 21, 2022 (publication date) through May 17, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Theofilis P, Vordoni A, Kalaitzidis RG. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations. World J Gastroenterol 2022; 28(39): 5691-5706 [PMID: 36338895 DOI: 10.3748/wjg.v28.i39.5691] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v28/i39/5691.htm |
| Number | Citing Articles |
| 1 |
Panagiotis Theofilis, Aikaterini Vordoni, Vasilis Tsimihodimos, Rigas G. Kalaitzidis. Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk Markers. High Blood Pressure & Cardiovascular Prevention 2023; 30(1): 63 doi: 10.1007/s40292-023-00558-5
|
| 2 |
Zhipeng Chen, Feng Zhao, Siqi Li. Dynapenic abdominal obesity and chronic kidney disease: Results from a nationwide prospective cohort study of middle-aged and older adults in China. Archives of Gerontology and Geriatrics 2025; 136: 105879 doi: 10.1016/j.archger.2025.105879
|
| 3 |
Anil Pareek, Siddharth Nikam, Ravishankar Akolekar. Is intervening inflammatory pathways a way to treat type 2-diabetes. International Journal of Basic & Clinical Pharmacology 2025; 14(3): 441 doi: 10.18203/2319-2003.ijbcp20251074
|
| 4 |
Sharon Olabisoye Oladipupo, Emmanuel Henry Ezenabor, Adebola Busola Ojo, Akingbolabo Daniel Ogunlakin, Oluwafemi Adeleke Ojo. Interplay of the pathophysiological mechanisms of non-alcoholic fatty liver disease, diabetes mellitus, and inflammation: A growing threat to public health. Obesity Medicine 2025; 55: 100613 doi: 10.1016/j.obmed.2025.100613
|
| 5 |
Damon J. DiSabato, Christina M. Marion, Katherine A. Mifflin, Anthony N. Alfredo, Kyleigh A. Rodgers, Kristina A. Kigerl, Phillip G. Popovich, Dana M. McTigue. System failure: Systemic inflammation following spinal cord injury. European Journal of Immunology 2024; 54(1) doi: 10.1002/eji.202250274
|
| 6 |
Maria Sole Valentino, Pierluigi Marzuillo, Claudia Esposito, Mario Bartiromo, Michele Nardolillo, Annalisa Valentina Villani, Alessandro Maresca, Giuseppe Furcolo, Stefano Guarino, Emanuele Miraglia del Giudice, Anna Di Sessa. The Impact of COVID-19 Pandemic Lockdown on the Relationship between Pediatric MAFLD and Renal Function. Journal of Clinical Medicine 2023; 12(5): 2037 doi: 10.3390/jcm12052037
|
| 7 |
Carolina M. Perdomo, Nerea Martin-Calvo, Ana Ezponda, Francisco J. Mendoza, Gorka Bastarrika, Nuria Garcia-Fernandez, José I. Herrero, Inmaculada Colina, Javier Escalada, Gema Frühbeck. Epicardial and liver fat implications in albuminuria: a retrospective study. Cardiovascular Diabetology 2024; 23(1) doi: 10.1186/s12933-024-02399-5
|
| 8 |
Kristine Griffett, Thomas P. Burris. Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases. Frontiers in Medicine 2023; 10 doi: 10.3389/fmed.2023.1102469
|
| 9 |
Mahmoud Ibrahim, Ebtesam M. Ba‐Essa, Jason Baker, Avivit Cahn, Antonio Ceriello, Francesco Cosentino, Melanie J. Davies, Robert H. Eckel, Luc Van Gaal, Peter Gaede, Yehuda Handelsman, Samuel Klein, Richard David Leslie, Paolo Pozzilli, Stefano Del Prato, Francesco Prattichizzo, Oliver Schnell, Petar M. Seferovic, Eberhard Standl, Abraham Thomas, Jaakko Tuomilehto, Paul Valensi, Guillermo E. Umpierrez. Cardio‐renal‐metabolic disease in primary care setting. Diabetes/Metabolism Research and Reviews 2024; 40(3) doi: 10.1002/dmrr.3755
|
| 10 |
Amedeo Lonardo. Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review. Metabolism and Target Organ Damage 2024; 4(2) doi: 10.20517/mtod.2024.07
|
| 11 |
Panagiotis Theofilis, Aikaterini Vordoni, Rigas G. Kalaitzidis. Trimethylamine N-Oxide Levels in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Metabolites 2022; 12(12): 1243 doi: 10.3390/metabo12121243
|
| 12 |
Michele Nardolillo, Fabiola Rescigno, Mario Bartiromo, Dario Piatto, Stefano Guarino, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa. Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective. World Journal of Gastroenterology 2024; 30(15): 2081-2086 doi: 10.3748/wjg.v30.i15.2081
|
| 13 |
Josh Bilson, Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher. Steatotic liver disease, MASLD and risk of chronic kidney disease. Diabetes & Metabolism 2024; 50(1): 101506 doi: 10.1016/j.diabet.2023.101506
|
| 14 |
Suleiman Al Ashi, Ali A. Rizvi, Manfredi Rizzo. Altered kidney function in fatty liver disease: confronting the “MAFLD-renal syndrome”. Frontiers in Clinical Diabetes and Healthcare 2025; 5 doi: 10.3389/fcdhc.2024.1539117
|
| 15 |
Anna Di Sessa, Sarah Zarrilli, Gianmario Forcina, Vittoria Frattolillo, Ornella Camponesco, Claudia Migliaccio, Serena Ferrara, Giuseppina Rosaria Umano, Grazia Cirillo, Emanuele Miraglia del Giudice, Pierluigi Marzuillo. Role of metabolic dysfunction-associated steatotic liver disease and of its genetics on kidney function in childhood obesity. International Journal of Obesity 2025; 49(4): 605 doi: 10.1038/s41366-024-01674-5
|
| 16 |
Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun. Bioactive metabolites: A clue to the link between MASLD and CKD?. Clinical and Molecular Hepatology 2025; 31(1): 56 doi: 10.3350/cmh.2024.0782
|